May 31, 2026 · Pediatric dermatology · DOI: 10.1111/pde.70285

Safety of Dupilumab and Risk of Cutaneous T-Cell Lymphoma in Pediatric Patients With Atopic Dermatitis: A Data-Driven Guide to Counseling Patients and Families

Listen to this summary

The authors investigate the safety of dupilumab in pediatric patients with atopic dermatitis, specifically addressing concerns about the potential increased risk of cutaneous T-cell lymphoma (CTCL) associated with the treatment. They aim to provide evidence-based recommendations for monitoring and counseling families, particularly in light of recent data and the challenges posed by the diagnostic overlap between atopic dermatitis and CTCL.

Maria Gnarra Buethe, Tyler Sy, Lawrence F Eichenfield

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play